BIO News and Press, Bio-Rad Laboratories Inc. Class A From 01/09/23

Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease TOKYO, Jan 9, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced Eisai has submitted a supplemental Biologics ...

FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., Jan 9, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that under the Accelerated Approval Pathway the U.S. Food ...

Malaysian Genomics Explores R&D Collaboration with SIRIM PETALING JAYA, Malaysia, Jan 9, 2023 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce a strategic cooperation wit...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the fourth quarter and full year 2022 on Thursday, February 16, 2023, following the close of the market. Management will discuss these ...

Summary Punishment of both Bio-Rad Laboratories, Inc. and Sartorius AG continued throughout the final stages of 2022. Bio-Rad Laboratories had an equally challenging Q3, setting up Q4 and FY22 numbers as key inflection points. Questions arise on whether it is the more efficient use ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, will present a company overview at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 20...

Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging TOKYO, Dec 22, 2022 - (JCN Newswire) - Astellas Pharma Inc. (TSE: 4503), Eisai Co., Ltd. (TSE: 4523), Daiichi Sankyo Company, Limited (TSE: 4568) a...

Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals TOKYO, Dec 20, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights f...

Novotech is Gold Sponsor at Biotech Showcase 2023 SYDNEY, AU, Dec 20, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023. Novotech CEO Dr. John Moller and experts from the Novotech US and Asia Pacif...

Olympus Named to Dow Jones Sustainability World Index for Two Consecutive Years TOKYO, Dec 16, 2022 - (JCN Newswire) - Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer and more fulfilling, announced that it has been selected...